Insights

Growing Market Presence Asieris Pharmaceuticals is actively expanding its strategic collaborations and launching new business units, particularly in gynecology and women's health, which indicates increasing market reach and potential demand for innovative diagnostic and therapeutic solutions.

Product Development Focus With recent drug application approvals such as Hexvix in China and a robust pipeline targeting genitourinary diseases, there is significant opportunity to offer specialized treatments, diagnostic tools, and complementary solutions that align with their focus on first-in-class and innovative products.

Healthcare Technology Adoption The company employs advanced tech stacks and has a strategic partnership with ReviR Therapeutics for novel splicing therapies, highlighting their openness to integrating cutting-edge healthcare technologies, creating openings for digital health tools, diagnostics, and platform-based solutions.

Leadership & Expansion Recent hires, such as key executive appointments including a Chief Development Officer and leadership in women's health, suggest active organizational growth and strategic realignment, which could benefit from tailored engagement around clinical development, research tools, and healthcare innovation.

Funding & Revenue Opportunities With a revenue range of 50 to 100 million dollars and over 100 million dollars in funding, Asieris is positioned for further R&D and market entry efforts, offering opportunities for partnership in clinical trials, supply chain solutions, and innovative pharmaceutical manufacturing services.

Asieris Pharmaceuticals Tech Stack

Asieris Pharmaceuticals uses 8 technology products and services including W3 Total Cache, Microsoft 365, JSON-LD, and more. Explore Asieris Pharmaceuticals's tech stack below.

  • W3 Total Cache
    Caching
  • Microsoft 365
    Email
  • JSON-LD
    Javascript Frameworks
  • Swiper
    Javascript Libraries
  • imagesLoaded
    Javascript Libraries
  • jQuery Migrate
    Javascript Libraries
  • three.js
    Programming Languages
  • WPML
    Web Platform Extensions

Media & News

Asieris Pharmaceuticals's Email Address Formats

Asieris Pharmaceuticals uses at least 2 format(s):
Asieris Pharmaceuticals Email FormatsExamplePercentage
FLast@asieris.cnJDoe@asieris.cn
79%
FirstLast@asieris.cnJohnDoe@asieris.cn
10%
First.Last@asieris.cnJohn.Doe@asieris.cn
11%
First.Last@asieris.comJohn.Doe@asieris.com
38%
FLast@asieris.comJDoe@asieris.com
12%
First.Last@asieris.comJohn.Doe@asieris.com
38%
FLast@asieris.comJDoe@asieris.com
12%

Frequently Asked Questions

Where is Asieris Pharmaceuticals's headquarters located?

Minus sign iconPlus sign icon
Asieris Pharmaceuticals's main headquarters is located at 201 King of Prussia Road, Suite 650. The company has employees across 4 continents, including AsiaNorth AmericaEurope.

What is Asieris Pharmaceuticals's official website and social media links?

Minus sign iconPlus sign icon
Asieris Pharmaceuticals's official website is asieris.com and has social profiles on LinkedInCrunchbase.

What is Asieris Pharmaceuticals's NAICS code?

Minus sign iconPlus sign icon
Asieris Pharmaceuticals's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Asieris Pharmaceuticals have currently?

Minus sign iconPlus sign icon
As of December 2025, Asieris Pharmaceuticals has approximately 201 employees across 4 continents, including AsiaNorth AmericaEurope. Key team members include Chief Operating Officer: J. Z.Head Of Hr: W. C.Head Of Analytical R&d: W. M.. Explore Asieris Pharmaceuticals's employee directory with LeadIQ.

What industry does Asieris Pharmaceuticals belong to?

Minus sign iconPlus sign icon
Asieris Pharmaceuticals operates in the Pharmaceutical Manufacturing industry.

What technology does Asieris Pharmaceuticals use?

Minus sign iconPlus sign icon
Asieris Pharmaceuticals's tech stack includes W3 Total CacheMicrosoft 365JSON-LDSwiperimagesLoadedjQuery Migratethree.jsWPML.

What is Asieris Pharmaceuticals's email format?

Minus sign iconPlus sign icon
Asieris Pharmaceuticals's email format typically follows the pattern of FLast@asieris.cn. Find more Asieris Pharmaceuticals email formats with LeadIQ.

How much funding has Asieris Pharmaceuticals raised to date?

Minus sign iconPlus sign icon
As of December 2025, Asieris Pharmaceuticals has raised $106M in funding. The last funding round occurred on Nov 11, 2020 for $106M.

When was Asieris Pharmaceuticals founded?

Minus sign iconPlus sign icon
Asieris Pharmaceuticals was founded in 2010.

Asieris Pharmaceuticals

Pharmaceutical ManufacturingPennsylvania, United States201-500 Employees

Asieris Pharmaceuticals, founded in March 2010, is a global innovative pharma company specializing in new drugs for the treatment of genitourinary tumors and other major diseases. We strive to improve human health and help people live a more dignified life. We aim to become a global pharma leader that integrates R&D, manufacturing and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.
 
The company has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus.
 
Asieris is also enhancing its pipeline for genitourinary diseases via proprietary R&D and strategic partnerships, while closely following cutting-edge technologies and therapeutics. The company strives to discover and identify unmet clinical needs, and adopts a forward-looking approach in product planning and life-cycle management. We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally.

Section iconCompany Overview

Headquarters
201 King of Prussia Road, Suite 650
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2010
Employees
201-500

Section iconFunding & Financials

  • $106M

    Asieris Pharmaceuticals has raised a total of $106M of funding over 5 rounds. Their latest funding round was raised on Nov 11, 2020 in the amount of $106M.

  • $50M$100M

    Asieris Pharmaceuticals's revenue is estimated to be in the range of $50M$100M

Section iconFunding & Financials

  • $106M

    Asieris Pharmaceuticals has raised a total of $106M of funding over 5 rounds. Their latest funding round was raised on Nov 11, 2020 in the amount of $106M.

  • $50M$100M

    Asieris Pharmaceuticals's revenue is estimated to be in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.